ID   BL
AC   CVCL_U802
SY   BLmel; BL mel
DR   cancercelllines; CVCL_U802
DR   Cosmic; 888987
DR   Cosmic; 897737
DR   Cosmic; 928724
DR   GEO; GSM170823
DR   Wikidata; Q54797091
RX   PubMed=1697409;
RX   PubMed=9331097;
RX   PubMed=9354451;
RX   PubMed=15048078;
RX   PubMed=15688405;
RX   PubMed=17516929;
RX   PubMed=19383913;
RX   PubMed=22383533;
RX   PubMed=23039341;
WW   http://biogps.org/dataset/1409/63-melanoma-cell-lines/
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=22383533).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu88Lys (c.262G>A); ClinVar=VCV000821566; Zygosity=Unspecified (PubMed=9354451).
CC   Omics: Transcriptome analysis by microarray.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 14
//
RX   PubMed=1697409;
RA   Chenevix-Trench G., Martin N.G., Ellem K.A.O.;
RT   "Gene expression in melanoma cell lines and cultured melanocytes:
RT   correlation between levels of c-src-1, c-myc and p53.";
RL   Oncogene 5:1187-1193(1990).
//
RX   PubMed=9331097;
RA   Salazar-Onfray F., Nakazawa T., Chhajlani V., Petersson M., Karre K.,
RA   Masucci G., Celis E., Sette A., Southwood S., Appella E.,
RA   Kiessling R.;
RT   "Synthetic peptides derived from the melanocyte-stimulating hormone
RT   receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes
RT   that recognize naturally processed peptides on human melanoma
RT   cells.";
RL   Cancer Res. 57:4348-4355(1997).
//
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=15688405; DOI=10.1002/ijc.20873;
RA   Eskandarpour M., Kiaii S., Zhu C.-Y., Castro J., Sakko A.J., Hansson J.;
RT   "Suppression of oncogenic NRAS by RNA interference induces apoptosis
RT   of human melanoma cells.";
RL   Int. J. Cancer 115:65-73(2005).
//
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.K.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
//
RX   PubMed=19383913; DOI=10.1158/0008-5472.CAN-08-3746;
RA   Cedervall J., Jamil S., Prasmickaite L., Cheng Y.-F., Eskandarpour M.,
RA   Hansson J., Maelandsmo G.M., Ringborg U., Gulyas M., Zhen H.-S.,
RA   Kanter L., Ahrlund-Richter L.;
RT   "Species-specific in vivo engraftment of the human BL melanoma cell
RT   line results in an invasive dedifferentiated phenotype not present in
RT   xenografts.";
RL   Cancer Res. 69:3746-3754(2009).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//
RX   PubMed=23039341; DOI=10.1186/1476-4598-11-75;
RA   Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J.,
RA   Nomoto K., Pollock P.M.;
RT   "Sensitivity to the MEK inhibitor E6201 in melanoma cells is
RT   associated with mutant BRAF and wildtype PTEN status.";
RL   Mol. Cancer 11:75.1-75.15(2012).
//